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Guided tissue regenerationAbstract Aim: The purpose of the present study was to compare the regenerative potential of
noncontained periodontal infrabony defects treated with decalciﬁed freeze-dried bone allograft
(DFDBA) and barrier membrane with or without local doxycycline.
Methods: This study included 48 one- or two-wall infrabony defects from 24 patients (age:
30–65 years) seeking treatment for chronic periodontitis. Defects were randomly divided into two
groups and were treated with a combination of DFDBA and barrier membrane, either alone
(combined treatment group) or with local doxycycline (combined treatment + doxycycline group).
At baseline (before surgery) and 3 and 6 months after surgery, the pocket probing depth (PPD),
clinical attachment level (CAL), radiological bone ﬁll (RBF), and alveolar height reduction
(AHR) were recorded. Analysis of variance and the Newman–Keuls post hoc test were used for sta-
tistical analysis. A two-tailed p-value of less than 0.05 was considered to be statistically signiﬁcant.
Results: In the combined treatment group, the PPD reduction was 2.00 ± 0.38 mm (32%), CAL
gain was 1.25 ± 0.31 mm (17.9%), and RBF was 0.75 ± 0.31 mm (20.7%) after 6 months. In the
combined treatment + doxycycline group, these values were 2.75 ± 0.37 mm (44%),
1.5 ± 0.27 mm (21.1%), and 1.13 ± 0.23 mm (28.1%), respectively. AHR values for the groups
without and with doxycycline were 12.5% and 9.4%, respectively.
Conclusion: There was no signiﬁcant difference in the regeneration of noncontained periodontal
infrabony defects between groups treated with DFDBA and barrier membrane with or without
doxycycline.
Crown Copyright ª 2015 Production and hosting by Elsevier B.V. on behalf of King Saud University.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Bone grafts can be used for reconstructing periodontal osseous
defects and achieving new attachment for connective tissue
ﬁbers. Among the available graft materials, only autogenous
bone and decalciﬁed freeze-dried bone allograft (DFDBA)
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regenerative materials (Darby, 2011; Rosen et al., 2000). In
addition to patient-speciﬁc characteristics (plaque control,
smoking habits, wound healing potential), factors related to
the defect morphology, particularly the morphology of the
remaining wall in the defect, may play important roles in
regenerative outcomes (Cortellini et al., 1998; Park et al.,
2014).
DFDBA has osteoinductive activity because it contains
bone morphogenic proteins (BMPs). Decalciﬁcation of the
graft exposes and may activate bone-inductive proteins in the
bone matrix (Behfarnia et al., 2012). Studies have conﬁrmed
that the use of DFDBA can lead to the formation of new
attachments (Darby, 2011). There are several advantages to
using bone grafts with guided tissue regeneration (GTR).
For example, bone grafts prevent membrane collapse inside
the defect, improve space maintenance and clot stabilization,
and facilitate the proliferation of osteogenic progenitor cells
(Paolantonio et al., 2010; Sculean et al., 2008). Polylactic
acid/polyglycolic acid (PLA/PGA) membrane is a synthetic
bioabsorbable barrier membrane made from a copolymer of
glycolide and lactide. Many studies have used PLA/PGA
membrane in the treatment of infrabony defects (Aimetti
et al., 2005; Kim et al., 2002).
Doxycycline facilitates regenerative therapy by initiating
demineralization of the bone surface layer. This demineraliza-
tion results in the release of osteogenic factors, such as trans-
forming growth factor (TGF), insulin-like growth factor, and
BMPs, which trigger bone induction (Kaur and Sikri, 2013).
Doxycycline has anticollagenolytic and antiproteolytic proper-
ties that enhance the bone-forming ability via osteoblast cell
chemotaxis and reduced bone resorption (Chaturvedi et al.,
2008).
It could be beneﬁcial to use local doxycycline with a bone
graft in anatomically unfavorable infrabony defects, which
are more vulnerable to oral contamination due to their non-
contained nature and have inherently less osteogenic potential
due to the smaller amount of remaining wall. However, little
data are available comparing the combined use of DFDBA
plus barrier membrane with and without local doxycycline in
human periodontal infrabony defects. Therefore, the present
study was undertaken to explore the beneﬁcial effects of
combined therapy with local doxycycline in noncontained peri-
odontal infrabony osseous defects.2. Materials and methods
2.1. Patients
This study included 48 infrabony periodontal defects (27 two-
wall and 21 one-wall defects) in 24 patients (14 males and 10
females; age: 30–65 years) who were seen at the Outpatient
Department of Periodontics, Aligarh Muslim University,
Aligarh for treatment of moderate to severe chronic periodon-
titis. Inclusion criteria were the presence of contralateral one-
and two-wall intraosseous infrabony defects with a pocket
probing depth (PPD) of 5 mm or more and a defect depth
(as assessed through bone probing) of 3 mm or more, as well
as fewer than 20% of gingival sites exhibiting bacterial plaque
(%PL+) or bleeding on probing (%BOP+). Exclusion crite-
ria were any systemic disease, medication use, pregnancy orlactation, smoking habit, previous periodontal treatment,
and furcation (according to Glickman). After recruitment of
patients, the study protocol, risks, beneﬁts, and procedures
were explained, and written informed consent was obtained
from every patient. All examinations, treatments, and proce-
dures associated with this study followed the principles of
the Declaration of Helsinki. The study was reviewed and
approved by the ethics committee of Aligarh Muslim
University.
2.2. Study design
The study was designed as a randomized, double-blinded study
comparing the periodontal outcomes obtained when using
DFDBA plus a barrier membrane with or without local doxy-
cycline in the treatment of intrabony defects. A split-mouth
design was used. Defects were randomly divided into two
groups by a computer-generated system, according to treat-
ment. The control group was treated with DFDBA and a bar-
rier membrane (combined treatment group). The test group
was treated with DFDBA, barrier membrane, and local doxy-
cycline (combined treatment + doxycycline group). Defects
were analyzed clinically and radiologically at baseline (before
surgery) and 3 and 6 months after regenerative surgery by a
single investigator for each surgical site.
2.3. Clinical and radiographic parameters
Every patient received a complete periodontal examination,
oral hygiene instructions, and a thorough scaling and root
planing session prior to surgery. Nonsurgical therapy and pre-
surgery recordings were performed 4 weeks before surgery.
Presurgical evaluation included %PL+ or %BOP+ sites,
PPD, and clinical attachment level (CAL). Parameters associ-
ated with the defects were not signiﬁcantly different between
the control and test groups. PPD and CAL were recorded to
the nearest millimeter with the help of a manual UNC-15
probe (Hu-Friedy Mfg. Inc., Chicago, IL) at the deepest point
of the periodontal pocket, from the vertical groove in the
acrylic stent on the occlusal surface.
Radiographic parameters included the radiographic bone
ﬁll (RBF) and resorption of alveolar bone height (alveolar
height reduction, AHR). The distance from the reference point
(radiographic cemento-enamel junction, CEJ) to the base of
the defect (BD) and to the crest of the bone (CB), and the dis-
tance from the CB to the BD (radiologic defect depth, RDD)
were measured. RBF was deﬁned as the difference between the
pre- and post-treatment measurements of RDD. AHR was
deﬁned as the difference between the pre- and post-treatment
measurements of the distance from the radiologic CEJ to the
alveolar bone height (ABH). Intraoral periapical radiographs
were taken with the parallel cone technique and a customized
ﬁlm holder. An effort was made to obtain similar projection
geometries and optical densities for the pre- and post-
operative radiographs. Parameters were recorded to the near-
est millimeter with a radiological grid (1 · 1 mm).
2.4. Surgical protocol
After administration of local anesthesia, intrasulcular incisions
were made, and full-thickness mucoperiosteum ﬂaps were
Figure 1 Pre operative pocket probing depth in DFDBA+
barrier membrane group.
Figure 2 Infra bony defect mesial to 2nd premolar.
Figure 3 Barrier membrane placement over bone graft in defect
area.
Figure 4 Pocket probing depth after 6 months in DFDBA+
barrier membrane group.
Treatment of infrabony periodontal defects 157reﬂected buccally and lingually. Care was taken to preserve the
interdental papilla. Thorough debridement was carried out in
the infrabony defect areas.
For the combined treatment + doxycycline group,
DFDBA (LifeNet Health, Virginia Beach, VA) and doxycy-
cline pellets were mixed at a 1:4 volume ratio (Evanas et al.,
1989) of doxycycline to DFDBA. The mixture was reconsti-
tuted with sterile saline water and placed in the defect up to
the alveolar crest. A fresh PLA/PGA membrane (Polyglyctin
910, Ethicon, Johnson & Johnson, Norderstedt, Germany)
was trimmed according to the defect morphology and adapted
over the defect, which was ﬁlled with graft beyond 2–3 mm of
the perilesional bone margin both apically and laterally. For
the combined treatment group, the same procedure wasperformed by mixing bone graft with placebo at the same ratio
as doxycycline.
For ﬂap closure, 3–0 black braided silk sutures were used.
Periodontal dressing was utilized for wound stabilization and
patient comfort (Figs. 1–6). The postoperative regimen
included verbal and written instructions. Patients were pre-
scribed 500 mg of amoxicillin and 125 mg of clavulanic acid
three times a day for 5 days, and 0.12% chlorhexidine glu-
conate mouth rinse twice daily for 2 weeks. Sutures were
removed after 7 days. Patients were placed on a maintenance
program of biweekly professional tooth cleaning.
2.5. Statistical analysis
Groups were compared by repeated-measures analysis of vari-
ance (ANOVA). The signiﬁcance of mean differences within
and between groups was determined by the Newman–Keuls
Figure 5 Pre operative radiograph of DFDBA+ barrier mem-
brane group.
Figure 6 Post operative radiograph of DFDBA+ barrier
membrane group.
Table 1 PPD, CAL, RDD, ABH (mm) summary
(Mean ± SE, n= 24), and signiﬁcance (p value) of mean
difference between groups at three different periods.
DFDBA+ barrier membrane group
Baseline 3 month 6 month Mean change
(%)
PPD 6.25 ± 0.67 4.25 ± 0.59 4.25 ± 0.56 32.0
CAL 7.00 ± 0.71 5.88 ± 0.58 5.75 ± 0.59 17.9
RDD 3.63 ± 0.50 3.38 ± 0.42 2.88 ± 0.35 20.7
ABH 2.63 ± 0.50 2.88 ± 0.52 3.00 ± 0.60 12.5
DFDBA+ barrier membrane + doxycycline group
PPD 6.25 ± 0.62 3.38 ± 0.18 3.50 ± 0.27 44.0
CAL 7.13 ± 0.81 5.63 ± 0.56 5.63 ± 0.56 21.1
RDD 4.00 ± 0.42 3.75 ± 0.53 2.88 ± 0.40 28.1
ABH 3.63 ± 0.94 3.75 ± 0.88 4.00 ± 0.98 9.4
Signiﬁcance (p value) of mean diﬀerence between without vs. with
doxycycline group
PPD 1.000 0.748 0.732 –
CAL 0.884 0.991 0.884 –
RDD 0.793 0.914 1.000 –
ABH 0.497 0.497 0.178 –
PPD – pocket probing depth; CAL – clinical attachment level;
RDD – radiographic defect depth; ABH – alveolar bone height; SE
– standard error.
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was considered to be statistically signiﬁcant.
3. Results
All patients maintained a high standard of plaque control throughout
the study. All defects healed uneventfully, with no clinical or radio-
graphic indication of ankylosis.
In the combined treatment group, the %PL+ and %BOP+ sites
were 13.8% and 14.9%, respectively, at baseline, and 13.3% and
14.4%, respectively, after 6 months (p> 0.05). For the combinedtreatment + doxycycline group, the %PL+ and %BOP+ sites were
13.9% and 14.5%, respectively, at baseline, and 12.5% and 13.3%,
respectively, after 6 months (p> 0.05). Comparing the clinical and
radiographic measurements at different time points, statistically signif-
icant improvements of soft tissue parameters were obtained between
baseline and 3 or 6 months. Signiﬁcant changes in hard tissue param-
eters were found between 3 and 6 months.
For the control group, the PPD reduction was 2.00 ± 0.38 mm
(32%), CAL gain was 1.25 ± 0.31 mm (17.9%), and RBF was
0.75 ± 0.31 mm (20.7%). For the test group, these values were
2.75 ± 0.37 mm (44%), 1.5 ± 0.27 mm (21.1%), and
1.13 ± 0.23 mm (28.1%), respectively for the comparison of base line
and 6 months. The AHR values in the groups without and with doxy-
cycline were 0.38 and 0.37 mm, respectively. These results and their sig-
niﬁcance (p-values) at different time intervals are summarized in
Table 1. There were no signiﬁcant differences in PPD, CAL, RDD,
or ABH between the control and test groups at any time point
(Table 2).
For two-wall defects, changes of 31.4% and 46.1% in PPD, 17.5%
and 21.8% in CAL, 27.7% and 27.7% in RDD, and 10% and 16.6%
in ABH were recorded for the control and test groups, respectively.
For one-wall defects, changes of 35.4% and 41.7% in PPD, 18.8%
and 20.0% in CAL, 9.0% and 28.5% in RDD, and 18.3% and
5.88% in ABH were recorded for the control and test groups, respec-
tively (Table 3).
4. Discussion
Regenerative outcomes of noncontained periodontal infrab-
ony defects were not signiﬁcantly different between groups
treated with DFDBA and barrier membrane with or without
local doxycycline. Both groups showed signiﬁcant improve-
ments in parameters after 6 months compared to baseline.
Better results for one- and two-wall defects were obtained in
the group treated with doxycycline. Two-wall defects showed
Table 2 For each group, signiﬁcance (p value) of mean
difference in PPD, CAL, RDD, ABH between the periods
(within groups).
DFDBA+ barrier membrane group
PPD CAL RDD ABH
Baseline vs. 3 months 0.001 0.001 0.560 0.524
Baseline vs. 6 months 0.001 0.001 0.048 0.258
3 month vs. 6 months 1.000 0.605 0.254 0.497
DFDBA+ barrier membrane group doxycycline
Baseline vs. 3 months 0.001 0.001 0.307 0.497
Baseline vs. 6 months 0.001 0.001 0.001 0.111
3 month vs. 6 months 0.937 1.000 0.010 0.178
PPD – pocket probing depth; CAL – clinical attachment level;
RDD – radiographic defect depth; ABH – alveolar bone height.
Table 3 Distribution and data for 2 wall and 1 wall defects.
DFDBA+ barrier
membrane group
DFDBA+ barrier
membrane + doxycycline
group
Two wall defects (14) Two wall defects (13)
(mm) Base
line
6 months Change
(%)
Base
line
6 months Change
(%)
PPD 7.00 4.80 31.4 6.50 3.50 46.1
CAL 8.00 6.60 17.5 8.00 6.25 21.8
RDD 3.60 2.60 27.7 4.50 3.25 27.7
ABH 2.00 2.20 10 3.00 2.50 16.6
One wall defects (10) One wall defects (11)
PPD 5.00 3.33 35.4 6.00 3.50 41.7
CAL 5.33 4.33 18.8 6.25 5.00 20.0
RDD 3.66 3.33 9.0 3.50 2.50 28.5
ABH 3.66 4.33 18.3 4.25 4.50 5.88
PPD – pocket probing depth; CAL – clinical attachment level;
RDD – radiographic defect depth; ABH – alveolar bone height.
Treatment of infrabony periodontal defects 159greater bone ﬁll and less crestal resorption with both treatment
modalities.
Our ﬁndings are in agreement with previous studies report-
ing signiﬁcant improvements in the clinical parameters of
infrabony defects treated by DFDBA with tetracycline
(Drury and Yukna, 1991; Mabry et al., 1985; Masters et al.,
1996; Waleed et al., 1989). The biological rationale for using
doxycycline as an adjunctive to regenerative therapy is its
antimicrobial, anticollagenolytic, and ﬁbroblast-stimulating
activities. The antimicrobial component makes doxycycline
the drug of choice in periodontal regenerative therapy. The
anticollagenolytic effect may act to inhibit collagenase and
other host-derived matrix metalloproteinases that are responsi-
ble for alveolar bone resorption (Chaturvedi et al., 2008; Kaur
and Sikri, 2013). Doxycycline protects alpha-1 proteinase inhi-
bitor from proteolytic inactivation in the gingival crevicular
ﬂuid, and inhibits the production and scavenging of reactive
oxygen radicals generated by neutrophils. Increased ﬁbronec-
tin binding to tetracycline-conditioned roots promotes the
attachment of ﬁbroblasts and inhibits epithelial cell attach-
ment (Lee et al., 1997; Takahashi et al., 2006).Studies have repeatedly demonstrated that using bone
grafts combined with barrier membranes improves the regener-
ative parameters of noncontained infrabony periodontal
defects (Chen et al., 1995; Lundgren and Slotte, 1999;
Paolantonio, 2002; Trejo et al., 2000). In contrast to our
results, Mellado et al. (1995) found a nonsigniﬁcant difference
in new bone formation. The osteoinductive property of
DFDBA is due to BMPs, which are members of the TGF-b
super family. BMPs are powerful inducers of endochondral
bone differentiation and act as soluble signals of tissue mor-
phogenesis, sculpting the multicellular mineralized structures
of periodontal tissues by inserting functionally oriented peri-
odontal ligament ﬁbers into the newly formed cementum
(Chen et al., 2004; Yukna and Vastardis, 2005). PLA/PGA
membrane is a synthetic bioabsorbable barrier membrane
made from a copolymer of glycolide and lactide. This mem-
brane is broken down by hydrolytic degradation. The use of
bioresorbable membranes prevents the need of a second sur-
gery for membrane removal. Many studies have used
PLA/PGA membrane in the treatment of infrabony defects
(Aimetti et al., 2005; Kim et al., 2002).
Adequate results have been reported on the association
between the number of remaining defect-containing bony walls
and the regenerative potential of periodontal infrabony
defects. We selected one- and two-wall periodontal infrabony
defects because three-wall infrabony defects have been
reported to heal more favorably due to the adequate source
of osteoprogenitor cells (Kornman and Robertson, 2000;
Tonetti et al., 1993). Unfavorable defects, when present, are
more exchangeable and susceptible to the oral environment.
Thus, ﬁlling materials would have a greater chance to becom-
ing contaminated, leading to an incomplete bone ﬁll (Aimetti
et al., 2005; Kornman and Robertson, 2000; Tonetti et al.,
1993). Local doxycycline was added to the bone graft to over-
come these shortcomings. The one- and two-wall defects
showed less support to the GTR membrane; therefore, we used
ﬁlling material beneath the membrane for better positioning of
the barrier membrane.
The results of our small cohort study are less striking than
those of previous studies, perhaps due to variations in several
factors (e.g., patient selection, defect characteristics, data col-
lection procedures, biochemical characteristics of grafted
materials, surgery, and patient attitudes toward treatment)
that inﬂuence the extent of clinical attachment gain and bone
growth after grafting (Kornman and Robertson, 2000;
Tonetti et al., 1993). All surgeries were performed by a single
well-experienced periodontist to minimize interoperator vari-
ability. Furthermore, the regenerative potential of DFDBA
therapy depends on the osteoinductivity of the bone graft sam-
ples, which may vary based on donor age, previous pathology
and/or drug therapy, genetic variation, and the length of time
required to harvest the cadaver bone (Jergesen et al., 1991;
Schwartz et al., 1996). Finally, the validity of this study would
be improved if the defect width had been considered. However,
it would have been very difﬁcult to obtain similar defects with
standardized depths, widths, and morphologies.5. Conclusion
For periodontal regeneration of noncontained infrabony
defects, there were no signiﬁcant clinical or radiologic
160 A. Agarwal, N.D. Guptadifferences between defects treated with DFDBA and barrier
membrane with or without local doxycycline.
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